Pediatric cancers in the new millennium: Dramatic progress, new challenges

ONCOLOGY

Volumn 21, Issue 7, 2007, Pages 809-820

  McGregor, Lisa M ^a,b   Metzger, Monika L ^a,b   Sanders, Robert ^a,b   Santana, Victor M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COSMEGAN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; RITUXIMAB; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CLINICAL TRIAL; EPENDYMOMA; EUROPE; EWING SARCOMA; GLIOMA; HODGKIN DISEASE; HUMAN; JAPAN; MEDULLOBLASTOMA; MINIMAL RESIDUAL DISEASE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; SOCIAL PSYCHOLOGY; SOFT TISSUE SARCOMA; UNITED STATES; ADOLESCENT; CANCER STAGING; CHILD; DISEASE FREE SURVIVAL; MORTALITY; NEOPLASM; PATHOLOGY; SURVIVOR;

ADOLESCENT; CHILD; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM STAGING; NEOPLASMS; SURVIVORS;

EID: 34948846148     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin 56:106-130, 2006.
2. Ries LAG, Percy CL, Bunin GR: in Ries LAG, Smith MA, Gurney JG, et al (eds): Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995, pp 1-16. Bethesda, Md; National Cancer Institute, SEER Program; 1999.
3. Bleyer WA: The impact of childhood cancer on the United States and the world. CA Cancer J Clin 40:355-367, 1990.
4. Murphy SB: The national impact of clinical cooperative group trials for pediatric cancer. Med Pediatr Oncol 24:279-280, 1995.
5. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-178, 2006.
6. Silverman LB, Gelber RD, Dalton VK, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 97:1211-1218, 2001.
7. Willenbrock H, Juncker AS, Schmiegelow K, et al: Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays. Leukemia 18:1270-1277, 2004.
8. Brown P, Levis M, Shurtleff S, et al: FLT3 Inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 105:812-820, 2005.
9. Rieter A, Schrappe M, Ludwig WD, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994.
10. Pui CH, Relling MV, Evans WE: Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 15:741-756, 2002.
11. Willman KY, Cox RS, Donaldson SS: Radiation induced height impairment in pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys 28:85-92, 1994.
12. Donaldson SS, Link MP: Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol 5:742-749, 1987.
13. Donaldson SS, Hancock SL: Second cancers after Hodgkin's disease in childhood. N Engl J Med 334:792-794, 1996.
14. Friedman DL, Constine LS: Late effects of treatment for Hodgkin lymphoma. J Natl Compr Canc Netw 4:249-257. 2006.
15. Friedberg JW, Fischman A, Neuberg D, et al: FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison. Leuk Lymphoma 45:85-92, 2004.
16. Krasin MJ, Hudson MM, Kaste SC: Positron emission tomography in pediatric radiation oncology: Integration in the treatment-planning process. Pediatr Radiol 34:214-221, 2004.
17. Longo DL, Duffey PL, Young RC, et al: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210-218, 1992.
18. Schmitz N, Pfistner B, Sextro M, et al: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 359:2065-2071, 2002.
19. Sandlund JT, Downing JR, Crist WM: Non-Hodgkin's lymphoma in childhood. N Engl J Med 334:1238-1248, 1996.
20. Murphy SB, Fairclough DL, Hutchison RE, et al: Non-Hodgkin's lymphomas of childhood: An analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 7:186-193, 1989.
21. Pinkerton R: Continuing challenges in childhood non-Hodgkin's lymphoma Br J Haematol 130:480-488, 2005.
22. Leverger G, Patte C: Therapeutic progress in acute lymphoblastic leukemias and stage IV Burkitt-type lymphomas in children. Bull Acad Natl Med 187:743-755, 2003.
23. Weinstein JL, Katzenstein HM, Cohn SL: Advances in the diagnosis and treatment of neuroblastoma. Oncologist 8:278-292, 2003.
24. Schmidt ML, Lal A, Seeger RC, et al: Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group Study. J Clin Oncol 23:6474-6480, 2005.
25. Matthay KK, Villabianca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis- retinoic acid. Children's Cancer Group. N Engl J Med 341:1165-1173, 1999.
26. Berthold F, Hero B, Kremens B, et al: Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett 197:11-17, 2003.
27. Cheung NK, Kushner BH, Cheung IY, et al: Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 16:3053-3060, 1998.
28. Santana VM, Furman WL, Billups CA, et al: Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 23:4039-4047, 2005.
29. Clouse JW, Thomas PR, Griffith RC, et al: The changing management of Wilms' tumor over a 30-year period. 1949-1978. Cancer 56:1484-1489, 1985.
30. Green DM: The treatment of stages I-IV favorable histology Wilms' tumor. J Clin Oncol 22:1366-1372, 2004.
31. Dome JS, Cotton CA, Perlman EJ, et al: Treatment of anaplastic histology Wilms' tumor: Results from the fifth National Wilms' Tumor Study. J Clin Oncol 24:2352-2358, 2006.
32. Ritchey ML, Green DM, Thomas PR, et al: Renal failure in Wilms' tumor patients: A report from the National Wilms' Tumor Study Group. Med Pediatr Oncol 26:75-80, 1996.
33. Thomas PR, Tefft M, Compaan PJ, et al: Results of two radiation therapy randomizations in the third National Wilms' Tumor Study. Cancer 68:1703-1707, 1991.
34. Barr RD, Chalmers D, De Pauw S, et al: Health-related quality of life in survivors of Wilms' tumor and advanced neuroblastoma: A cross-sectional study. J Clin Oncol 18:3280-3287, 2000.
35. Green DM, Breslow NE, Beckwith JB, et al: Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: A report from the National Wilms' Tumor Study Group. J Clin Oncol 19:3719-3724, 2001.
36. Grundy PE, Breslow NE, Li S, et al: Loss of heterozygosity for chromosomes Ip and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 23:7312-7321, 2005.
37. Raney RB, Anderson JR, Barr FG, et al: Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 23:215-220, 2001.
38. Stevens MC: Treatment for childhood rhabdomyosarcoma: The cost of cure. Lancet Oncol 6:77-84, 2005.
39. Wolden SL, Anderson JR, Crist WM, et al: Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol 17:3468-3475, 1999.
40. Heyn R, Newton WA, Raney RB, et al: Preservation of the bladder in patients with rhabdomyosarcoma. J Clin Oncol 15:69-75, 1997.
41. Arndt CA, Donaldson SS, Anderson JR, et al: What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract? Cancer 91:2454-2468, 2001.
42. Wiener ES, Anderson JR, Ojimba JI, et al: Controversies in the management of paratesticular rhabdomyosarcoma: Is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg 10:146-152, 2001.
43. Crist WM, Anderson JR, Meza JL, et al: Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 19:3091-3102, 2001.
44. Breitfeld PP, Meyer WH: Rhabdomyosarcoma: New windows of opportunity. Oncologist 10:518-527, 2005.
45. Marina N, Gebhardt M, Teot L, Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9:422-441, 2004.
46. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600-1606, 1986.
47. Harris MB, Gieser P, Goorin AM, et al: Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group Study. J Clin Oncol 16:3641-3648, 1998.
48. Rougraff BT, Simon MA, Kneisl JS, et al: Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am 76:649-656, 1994.
49. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,072 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790, 2002.
50. Gitelis S, Neel MD, Wilkins RM, et al: The use of a closed expandable prosthesis for pediatric sarcomas. Chir Organi Mov 88:327-333, 2003.
51. Turc-Carel C, Aurias A, Mugneret F, et al: Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 32:229-238, 1988.
52. Thompson AD, Teitell MA, Arvand A, et al: Divergent Ewing' s sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. Oncogene 18:5506-5513, 1999.
53. Athale UH, Shurtleff SA, Jenkins JJ, et al: Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol 23:99-104, 2001.
54. Thacker MM, Temple HT, Scully SP: Current treatment of Ewing sarcoma. Expert Rev Anticancer Ther 5:319-331, 2005.
55. Paulussen M, Ahrens S, Craft AW, et al: Ewing's tumors with primary lung metastases: Survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 16:3044-3052, 1998.
56. Grier HE, Krailo MD, Tarbell NJ, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694-701, 2003.
57. Vezina LG: Neuroradiology of childhood brain tumors: New challenges. J Neurooncol 75:243-252, 2005.
58. Packer RJ: Progress and challenges in childhood brain tumors. J Neurooncol 75:239-242, 2005.
59. Packer RJ, Ater J, Allen J, et al: Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86:747-754, 1997.
60. Horn B, Heideman R, Geyer R, et al: A multi-institutional retrospective study of intracranial ependymoma in children: Identification of risk factors. J Pediatr Hematol Oncol 21:203-211, 1999.
61. Merchant TE, Mulhern RK, Krasin MJ, et al: Preliminary results from a phase II trial of conformai radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 22:3156-3162, 2004.
62. Gilbertson RJ, Bentley L, Hernan R, et al: ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 8:3054-3064, 2002.
63. Packer RJ, Goldwein J, Nicholson HS, et al: Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17:2127-2136, 1999.
64. Thomas PR, Deutsch M, Kepner JL, et al: Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 16:3004-3011, 2000.
65. Packer RJ, Gajjar A, Vezina G, et al: Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24:4202-4208, 2006.
66. Gajjar A, Chintagumpala M, Ashley D, et al: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 7:813-820, 2006.
67. Lamont JM, McManamy CS, Pearson AD. et al: Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10:5482-5493, 2004.
68. Ellison DW, Onilude OE, Lindsey JC, et al: Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23:7951-7957,2005.
69. Gajjar A, Hernan R, Kocak M, et al: Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22:984-993, 2004.
70. Duffner PK: Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 10:293-310, 2004.
71. Duffner PK, Horowitz ME, Krischer JP, et al: The treatment of malignant brain tumors in infants and very young children: An update of the Pediatric Oncology Group experience. Neuro-oncol 1:152-161, 1999.
72. Finlay JL, Zacharoulis S: The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: A historical-and futuristic-perspective. J Neurooncol 75:253-266, 2005.
73. Tekautz TM, Fuller CE, Blaney S, et al: Atypical teratoid/rhabdoid tumors (ATRT): Improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 23:1491-1499,2005.